Resumen

El objetivo de este estudio es evaluar la eficacia y seguridad de dos regímenes de tratamiento intravenoso de Anifrolumab versus placebo en pacientes adultos con nefritis lúpica (NL) proliferativa activa.

Descripción detallada

Se trata de un estudio de Fase 2, multicéntrico, multinacional, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de dos regímenes de tratamiento intravenoso (IV) de Anifrolumab versus placebo en combinación con el tratamiento estándar (SOC) con mycophenolate mofetil (MMF) y corticosteroides en pacientes adultos con nefritis lúpica (NL) proliferativa activa.

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 70 YearsSexo: ALL

Criterios de inclusión

Age 18 through 70 years at the time of screening
Fulfils at least 4 of the 11 criteria of the revised 1982 ACR classification criteria for SLE, at least one of which must be:
Positive antinuclear antibody (ANA) test (1:40 or higher) or
Elevated anti-dsDNA antibodies at screening (reported as equivocal or positive results), as per the centrallaboratory; or
Anti-Smith antibody at screening elevated to above normal (ie, positive or equivocal results) as per the central laboratory
Class III (±Class V) or Class IV (±Class V) LN according to the World Health Organisation (WHO) or 2003 ISN/RPS classification based on a renal biopsy obtained within 12 weeks prior to signing the ICF or during the screening period:
Urine protein to creatinine ratio \>1 gm/gm (113.17 mg/mmol), obtained on a 24-hour urine collection at screening
Estimated glomerular filtration rate ≥35 mL/min/1.73 m2
Must not have active or latent TB on either chest radiograph or by Quantiferon gold test
Women of childbearing potential must have a negative serum beta-hCG test at screening and negative urine pregnancy test prior to the first dose of sponsor-provided MMF.

Criterios de exclusión

Receipt of any investigational product (small molecule or biologic) or commercially available biologic agent within four weeks or 5 half lives prior to signing of the ICF, whichever is greater
Pure Class V membranous LN on a renal biopsy obtained within 12 weeks prior to signing ICF or during the screening period
Known intolerance to ≤1.0 gm/day of MMF
History of dialysis within 12 months prior to signing the ICF or expected need for renal replacement therapy (dialysis or renal transplant) within a 6 month period after enrolment
Subjects, who at the time of signing the ICF, received any of the following immunosuppressive therapies after their qualifying biopsy
Oral corticosteroids \>0.5 mg/kg/day for more than 8 weeks or
Oral or IV pulse methylprednisolone \>3.0 gm (cumulative dose) or
IV cyclophosphamide \>2 pulses of high-dose (≥0.5 gm/m2) or \>4 doses of low dose (500 mg every 2 weeks) or
Average MMF \>2.5 gm/day (\>1800 mg/day of enteric-coated mycophenolate sodium) for more than 8 weeks or
Tacrolimus \>4 mg/day for more than 8 weeks
Major surgery within 8 weeks before signing the ICF or major surgery planned during the study period
History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF
Confirmed positive test for hepatitis B or hepatitis C
Any severe herpes infection at any time prior to randomization
Opportunistic infection requiring hospitalisation or parenteral antimicrobial treatment within 3 years prior to randomization (vaginal, oral and skin candidiasis is not an exclusionreason).
History of cancer, apart from:
Squamous or basal cell carcinoma of the skin that has been successfully treated
Cervical cancer in situ that has been successfully treated
Concurrent enrolment in another clinical study with an IP within 4 weeks prior to ICF signing or within 5 half-lives of the IP used in that clinical study, whichever is longer.
During screening (within 30 days before Day 1 \[Week 0 visit\]), any of the following:
Aspartate transaminase (AST) \>2.5×upper limit of normal (ULN)
Alanine transaminase (ALT) \>2.5×ULN
Total bilirubin \>ULN (unless due to Gilbert's syndrome \[based on Investigator's judgement\])
Glycosylated haemoglobin (HbA1c) \>8% (or \>0.08) at screening (diabetic subjects only)
Neutrophil count \<1x103/μL (or \<1.0 GI/L)
Platelet count \<25x103/μL (or \<25 GI/L)
Haemoglobin \<8 g/dL (or \<80 g/L).

Estudio Multicéntrico, Aleatorizado, Doble Ciego, Controlado con Placebo, de Fase 2 para Evaluar la Eficacia y Seguridad de Anifrolumab en Pacientes Adultos con Nefritis Lúpica Proliferativa Activa

Resumen

Descripción detallada

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

Anifrolumab

Placebo

Ubicaciones

Research Site

Research Site

Research Site

Patrocinadores